Literature DB >> 1457361

Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.

R A Janssen1, D T Sleijfer, A A Heijn, N H Mulder, T H The, L de Leij.   

Abstract

The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced changes in peripheral blood leucocyte composition and phenotypes were comparable to those reported for intravenously given rIL-2. The present paper shows a correlation between the 'activation status' of the patient before therapy and eventual response.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1457361      PMCID： PMC1978045          DOI： 10.1038/bjc.1992.431

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  11 in total

1.  Low-dose regimen of interleukin-2 for metastatic renal carcinoma.

Authors:  D T Sleijfer; R A Janssen; P H Willemse; A Martens; L de Leij; E G de Vries; N H Mulder
Journal:  Lancet       Date:  1990-06-23       Impact factor: 79.321

2.  Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.

Authors:  T M Ellis; S P Creekmore; J D McMannis; D P Braun; J A Harris; R I Fisher
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

3.  In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.

Authors:  M T Lotze; M C Custer; S O Sharrow; L A Rubin; D L Nelson; S A Rosenberg
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

4.  Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.

Authors:  G Weil-Hillman; P Fisch; A F Prieve; J A Sosman; J A Hank; P M Sondel
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

5.  Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

Authors:  D T Sleijfer; R A Janssen; J Buter; E G de Vries; P H Willemse; N H Mulder
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

6.  Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.

Authors:  W J Urba; R G Steis; D L Longo; W C Kopp; A E Maluish; L Marcon; D L Nelson; H C Stevenson; J W Clark
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

7.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Authors:  P M Sondel; P C Kohler; J A Hank; K H Moore; N S Rosenthal; J A Sosman; R Bechhofer; B Storer
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

10.  Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.

Authors:  M C Favrot; V Combaret; S Negrier; I Philip; P Thiesse; C Freydel; J T Bijmann; C R Franks; A Mercatello; T Philip
Journal:  J Biol Response Mod       Date:  1990-04
View more
  2 in total

Review 1.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.